Closed transaction

Sysmex Corporation has acquired the shares of Hyphen BioMed SAS

Advised by
Client
Counterparty
Deal stage
Closed transaction
Service
Sell
Sector
Healthcare
Contact
aodin@ddacompany.com

Deal details

DDA & Company represented the shareholders of Hyphen BioMed SAS, a scientific company boasting an extended experience in the field of Thrombosis, Haemostasis and Auto-Immunity providing a comprehensive offering of diagnostic and research reagents, distributed worldwide, on its sale to Japanese listed Sysmex Corporation

DDA & Company latest deals

Buy-side advisory

Nutricia acquired Real Food Blends.

Where
United States of America
Year
2020
Sell-side advisory

Extens, Capital Croissance, Bpifrance acquired Albus (SNAL).

Where
France
Year
2017
Buy-side advisory

4ventsgroup acquired Meanings.

Where
France
Year
2017

More by DDA & Company

More deals in Healthcare

Sell-side advisory

Allied Group has acquired majority stake in Tzamal Medical.

Where
Israel
Year
2026
Sell-side advisory

PharmaX Solutions was sold to BioPhorum.

Where
Germany
Year
2026
Sell-side advisory

Nostos Genomics was sold to Limbus Medical Technologies (varvis®).

Where
Germany
Year
2025

More Healthcare

More deals in Asia-Pacific

Advisory

The Hosteller.

Where
India
Year
2026
Advisory

Olea.

Where
Singapore
Year
2026

More Asia-Pacific

Membership

Gain worldwide reach with CapFive M&A professionals

The professionals of CapFive have been carefully selected on the basis of reputation, relationships, proven track record and knowledge of local markets.

Become a member

Get in touch

Find an adviser.

From a first valuation to signed completion, CapFive member firms advise on sell-side, buy-side, corporate finance and debt.

Share what you are planning and we will connect you with an adviser who has done it before, and who can bring in colleagues across borders when the deal needs them.

Contact us